HIV Updates for Pharmacy PracticeMaximizing Your Role to Impact Patient Outcomes
Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
Aboud M, Orkin C, Podzamczer D, et al. Lancet HIV. 2019;6(9):e576-e587.
Boyd MA, Boffito M, Castagna A, Estrada V. HIV Med. 2019;20(suppl 1):3-11.
Brotherton AL, Shah RB, Garland J, et al. 27th Conference on Retroviruses and Opportunistic Infections (CROI) 2020; March 8-11, 2020; Boston, MA. Abstract 498.
RAPID antiretroviral therapy: high virologic suppression rates with immediate antiretroviral therapy initiation in a vulnerable urban clinic population.
Coffey S, Bacchetti P, Sachdev D, et al. AIDS. 2019;33(5):825-832.
Colasanti J, Sumitani J, Mehta CC, et al. 25th Conference on Retroviruses and Opportunistic Infections (CROI) 2018; March 4−7, 2018; Boston, MA. Abstract 1109.
Collins BC, Bronson HW, Martin EG. 24th Conference on Retroviruses and Opportunistic Infections (CROI) 2017; February 13-17, 2017; Seattle, WA. Abstract 962.
Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial.
Daar ES, DeJesus E, Ruane P, et al. Lancet HIV. 2018;5(7):e347-e356.
Eisinger RW, Dieffenbach CW, Fauci AS. JAMA. 2019;321(5):451-452.
Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1.
Eron JJ, Orkin C, Cunningham D, et al. Antiviral Res. 2019;170:104543.
Ford N, Migone C, Calmy A. et al. AIDS. 2018;32:17-23.
Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Gallant JE, Daar ES, Raffi F, et al. Lancet HIV. 2016;3(4):e158-e165.
Immediate versus deferred switching from a boosted protease inhibitor-based regimen to a dolutegravir-based regimen in virologically suppressed patients with high cardiovascular risk or age ≥50 years: final 96 week results of the NEAT022 study.
Gatell JM, Assoumou L, Moyle G, et al. Clin Infect Dis. 2019;68(4):597-606.
Horberg MA, Hurley LB, Towner WJ, et al. J Acquir Immune Defic Syndr. 2012; 60(2):183-190.
Switching to doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) maintains HIV-1 virologic suppression through 48 weeks: results of the DRIVE-SHIFT Trial.
Johnson M, Kumar P, Molina JM, et al; for the DRIVE-SHIFT Study Group. J Acquir Immune Defic Syndr. 2019;81(4):463-472.
Linkage and antiretroviral therapy within 72 hours at a federally qualified health center in New Orleans.
Halperin J, Butler I, Conner K, et al. AIDS Patient Care STDS. 2018;32(2):39-41.
Non-HIV comorbid conditions and polypharmacy among people living with HIV age 65 or older compared with HIV-negative individuals age 65 or older in the United States: a retrospective claims-based analysis.
Kong AM, Pozen A, Anastos K, et al. AIDS Pt Care STDS. 2019;33(3);93-103.
A pharmacist-led medication switch protocol in an academic HIV clinic: patient knowledge and satisfaction.
Lee SS, Havens JP, Sayles HR, et al. BMC Infect Dis. 2018;18(1):310.
A pharmacist-led program to evaluate and reduce polypharmacy and potentially inappropriate prescribing in older HIV-positive patients.
McNicholl IR, Gandhi M, Hare CB, et al. Pharmacotherapy. 2017;37(12):1498-1506.
Factors associated with antiretroviral therapy adherence among transgender women receiving HIV medical care in the United States.
Mizuno Y, Beer L, Huang P, Frazier EL. LGBT Health. 2017;4(3):181-187.
Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Molina JM, Ward D, Brar I, et al. Lancet HIV. 2018;5(7):e357-e365.
Why don't patients take their drugs? The role of communication, context and culture in patient adherence and the work of the pharmacist in HIV/AIDS.
Penn C, Watermeyer J, Evans M. Patient Educ Couns. 2011;83(3):310-318.
The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a US public health setting.
Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. J Acquir Immune Defic Syndr. 2017;74(1):44-51.
Current and emerging two-drug approaches for HIV-1 therapy in ART-naïve and ART-experienced, virologically suppressed patients.
Rossetti B, Montagnani F, De Luca A. Expert Opin Pharmacother. 2018;19(7):713-738.
Samuel O, Unonu JM, Dotson K, et al. J Natl Med Assoc. 2018;110(4):378-383.
Scheer S, Hsu L, Schwarcz S, et al. Clin Infect Dis. 2018;66(7):1027-1034.
Utrillo L, Vidal F, Puig T, Domingo P. Expert Opin Drug Saf. 2016;15(10):1349-1360.
HIV testing in community pharmacies and retail clinics: a model to expand access to screening for HIV infection.
Weidle PJ, Lecher S, Botts LW, et al. J Am Pharm Assoc. 2014; 54(5):486-492.
Supporting Patients With Newly Diagnosed HIV
Supporting the Patients’ Adherence and Retention in Care
The PCPs Role in Preventing HIV
What Do You Know About PrEP?
Optimizing Use of Clinical Evidence & Pharmacoeconomic Models in Managed Care
What Do You Know About PrEP?
Got it? Treat it!
The Critical Role of the Community Pharmacist
Bringing Local Communities Together to Eliminate Coinfection Through Knowledge and Partnerships.
Volume 1: Rapid ART Initiation: A New Addition to the HIV-Care Tool Box
Key Issues Impacting OB/GYN Practice
Hot Topics in HBV, HCV, and NASH
Volume II: Expanding Evidence for the Role of Rapid ART Initiation in HIV Practice
Why It Matters in OB/GYN Practice Today
A Treater’s Guide to Optimizing Care in the Aging Patient with Comorbidities
How the Pharmacist Can Make a Difference
HIV Can Be Prevented— Are You Doing Your Part?
Rapid Start ART — A New Model for HIV Care
Understanding the Growing Syndemic — Opioids, HCV, and HIV
A PrEP Primer
The PCP’s Role in HCV Elimination
What the Pharmacist Needs to Know about PrEP
The Rapid ART Standard of Care: From Evidence to Healthcare Equity
Building Bridges to Reach People Who Inject Drugs With the Goal to Eliminate HCV
Benefits, Barriers, & Best Practices in an Advancing Field
Practical Solutions Across the Spectrum of Care
A PEP/PrEP Training Guide for Pharmacists
A Critical Step Toward HCV Elimination
Considering the Patient, the Provider, and the Science